Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3737 - Potential clinical management changes in patients harboring locally advanced squamous-cell carcinoma of head and neck by incorporating pre and post chemoradiotherapy 18.FDG PET/CT: A prospective trial.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Ulisses Nicolau

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

U.R. Nicolau1, A.C.M.D. Queiroz1, T. Felismino1, E.P.N. Lima2, V.H.F. Jesus1, L. Cezana1, M.S. Alves1, A.C.A. Pellizzon1, P.N. Pinto3, G.M. Porto3, G.B. Carvalho4, C.A.L. Pinto5, V.S.E. Silva1, A.P. Guimarães1, T.B. Oliveira1, M.K. Ikeda4, T.F. Paiva Jr1, P.C. Bes1, L.P. Kowalski4

Author affiliations

  • 1 Medical Oncology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 2 Nuclear Medicine, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 3 Medical Radiology, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 4 Head And Neck Surgery, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
  • 5 Pathology Department, A. C. Camargo Cancer Center, 01509-010 - Sao Paulo/BR
More

Resources

Abstract 3737

Background

The utility of performing 18.FDG PET/CT in the tumor staging and as a clinical management tool in the post-12Th-week chemoradiotherapy (CRT) in patients (pts) harboring locally advanced squamous-cell carcinoima of head and neck (LASCCHN) has been established. The aim of this report is to evaluate the impact of incorporating a staging 18.FDG-PET/CT and post CRT, for pts harboring 7Thedition AJCC staged III-IVA/B treated in a single medical centre.

Methods

Patients harboring LASCCHN who underwent induction chemotherapy (IC) with triplet taxane-containing regimen followed by concurrent CRT were prospectively evaluated as part of the A.C. Camargo Cancer Center PET/CT trial. Our pts underwent three 18.FDG-PET/CT. First as a baseline, second after cycle-1 IC and third at 10 to 12 weeks after completion of CRT. Our primary objective was early 18.FDG-PET/CT tumor response assessment after cycle-1 IC, which has been reported elsewhere. Herein we report changes in clinical staging, radiotherapy and surgical management generated by baseline and post-therapy PET-CTs. All pts provided signed consent for trial participation.

Results

Between February 2010 and July 2013, 49 pts (41 oropharynx, 4 hypopharynx and 4 larynx) were recruited. Upstaging in neck lymph nodes were registered in 6 cases (12.2%): N0 to N1 in 2, N1 to N2b in 1, N1 to N2c in 1, N2a to N2c in 1, N2b to N2c in one. One patient harboring unilateral N3 had demonstrated bilateral lymph node disease. Downstaging N1 to N0 was registered in 2 pts. Suspected distant metastatic disease was registered in 2 cases (lung 1, bone 1). Primary occult tumor was identified in 3, and secondary synchronic colorectal tumor was diagnosed in one case. Radiotherapy planning changes were generated by detection of new regional metastatic lymph nodes or identification of primary tumor in 10 patients (20.4%). Post-radiotherapy 18.FDG PET/CT was able to detect residual lymph node disease and residual primary disease in 3 and 1 pts respectively.

Conclusions

These findings confirm the clinical utility of performing pre and post CRT 18.FDG PET/CT in pts harboring LASCCHN.

Clinical trial identification

Brazilian Clinical Trial Registry - ReBEC - RBR-9wwstd.

Legal entity responsible for the study

A.C. Camargo Cancer Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.